tbuckley/cabot-search huggingface dataset:
ドキソルビシン誘導マウス心筋症に対する内在脳下垂体アデニレートシクラーゼ活性化ポリペプチド(PACAP)の心臓保護作用
Authors: Mori Hiroyoshi, Nakamachi Tomoya, Ohtaki Hirokazu, Yofu Sachiko, Iso Yoshitaka, Maezawa Hideyuki, Honda Yuki, Wakatsuki Daisuke, Wakabayashi Kohei, Shimojima Hisa, Shimizu Nobuyuki, Asano Fuyuki, Satou Tokutada, Ebato Mio, Higashi Yukei, Suzuki Hiroshi, Takeyama Yoichi, Shioda Seiji
Journal: Circulation (2009)
An Italian cost-effectiveness analysis of paclitaxel albumin (nab®-paclitaxel) + gemcitabine vs gemcibatine alone for metastatic pancreatic cancer patients: The APICE study
Authors: C. Lazzaro, C. Barone, F. Caprioni, S. Cascinu, A. Falcone, E. Maiello, M. Milella, C. Pinto, M. Reni, G. Tortora
Journal: Annals of Oncology (2016)
A Risk Adapted Approach Utilizing Plerixafor in Autologous Peripheral Blood Stem Cell Mobilization.
Authors: Ivana Micallef, Stephen M Ansell, Francis Buadi, David Dingli, Angela Dispenzieri, Dennis Gastineau, Morie Gertz, Suzanne R. Hayman, William Hogan, David J Inwards, Patrick L Johnston, Shaji Kumar, Martha Q. Lacy, Mark R. Litzow, Luis Porrata, Robert Wolf, Teresa Miceli, Jeff Winters
Journal: Blood (2009)
198P Use of chemotherapy and mismatch repair deficiency testing in resected stage II colon cancer
Authors: L. Au, M. Grant, A. Haydon, K. Oliva, S. Wilkins, E. Segelov, Y. Antill, C. Peter, P. Ranchod, A. Polglase, M. Chin, F. Chip, S. Skinner, W. Roger, P. McMurrick, J. Shapiro
Journal: Annals of Oncology (2016)
Use of a community of practice (CoP) platform as a model in regional quality improvements in cancer surgery: The Ottawa model.
Authors: Michael Fung-Kee-Fung, Robin P. Boushey, Chris Morash, James Watters, Robin Morash, Marlene Mackey, Jennifer Smylie
Journal: Journal of Clinical Oncology (2012)

68 Background: The Ottawa CoP model for developing multidisciplinary practitioner networks and integrating them with organizational processes was established in 2007 as a platform improving access to quality cancer surgery in one of the health regions (population 1,276,370) of Ontario, Canada. The three inter-disciplinary CoP collaboratives in breast, colorectal, and prostate cancer involve 230 care providers from 9 hospitals performing over 2,000 cancer surgeries per year. Objectives: 1) to address lack of coordination and standardization of care, 2) develop a regional platform for quality initiatives, and 3) bridge the gap between academic and community hospitals. Methods: Using the model, an academic tertiary care hospital and eight community hospitals partnered to support a regional quality improvement initiative that combines 1) educational outreach with audit and feedback to address variations in practice and 2) a unique platform for knowledge generation and innovation. Regional interdisciplinary teams developed a set of regional quality indicators (18) linked to mutually agreed standards and pathways. Regional registry was established to provide data feedback on performance against both provincial and regional standards. Best practices, innovations, and implementation progress are reviewed through sustained interactions between CoP members. Patient and care provider surveys are conducted. Results: The development and implementation of regional care standards and clinical pathways for three disease sites in 9 hospitals. Regional pathway compliance ranged 65-94%. Other significant improvements include: rectal cancer surgery centralization (80-90% per annum), increase in use of sentinel lymph node biopsies in breast cancer surgery (60-77% per annum) and a decreased positive prostate cancer surgical margin rate form 45% to 22%. Compliance with provincial guidelines for colon cancer surgery improved (20% increase 2006/2007 vs. 2010/2011). Increase in patient access to high-quality cancer surgery closer to home. Conclusions: Participation in the regional CoPs is associated with quality improvements at the system, patient, and professional levels.
Impact on mortality of increasing surgical volumes within hospitals after regionalization of thoracic surgery in Ontario, Canada.
Authors: Anna Bendzsak, Nancy N. Baxter, Gail Darling, Peter Austin, David R. Urbach
Journal: Journal of Clinical Oncology (2012)

225 Background: The causal direction of the volume-outcome relationship in surgery has not yet been established. Our objective was to study the effect of absolute hospital volume of anatomic lung resections and volume changes within hospitals on mortality, length of stay (LOS), readmission (RA), and post-discharge visits to the emergency room (ER visits), during a period of regionalization for lung surgery in Ontario, Canada, to test the theory of "practice makes perfect". Methods: For each anatomic lung resection in Ontario from 2004-2010 we determined the volume change within hospital as the difference in hospital operative volume between the year immediately prior to the date of surgery and year prior to that (Dvolume). We used generalized estimating equations and logistic regression, controlling for clustering within hospitals, to examine the effect of Dvolume, patient factors and year on operative mortality, RA and ER visits. Negative binomial regression was used for LOS. The absolute effect of volume, measured as the 12-month hospital volume prior to each procedure, on outcomes was also examined with the same models. Results: Higher hospital volumes were associated with significant improvements in mortality and length of stay, (for increases of 10 cases, mortality OR=0.98 [95%CI: 0.96-1.00] and LOS RR=0.98 [95% CI: 0.97-0.99]), but not for RA or ER visits. However, increases in within-hospital volume did not lead to changes in mortality (OR=1.00, 95% CI: 0.96-1.10), RA (OR=1.00, 95% CI: 0.99-1.00), or ER visits (OR=0.99, 95% CI: 0.98-1.00). Volume increases within hospitals did lead to small improvements in LOS (RR=0.996, 95% CI: 0.993-0.999). Conclusions: Increasing volumes within hospitals did not lead to improvements in mortality in our study, but did result in small improvements in LOS. The decrease in LOS was likely appropriate as it was not associated with changes in RA or ER visits. A volume-outcome relationship between absolute hospital volume and improved mortality was observed, but was not explained by increasing volumes within hospitals; thus practice did not make perfect for mortality.
Coagulopathy in Acute Promyelocytic Leukemia: Strategies to Improve Assessment of Hemostatic Risk
Authors: Sachin David, Vandana Kamath, Uday Kulkarni, Ramya Vijayan, Anu Korula, Fouzia NA, Nisham PN, Alok Srivastava, Kavitha M Lakshmi, Poonkuzhali Balasubramanian, Biju George, Sukesh Nair, Vikram Mathews
Journal: Blood (2015)
116O Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor-positive (ER +)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC)
Authors: S.-A. Im, H. Mukai, I.H. Park, N. Masuda, C. Shimizu, S.B. Kim, Y.-H. Im, S. Ohtani, C.H. Bartlett, D.R. Lu, A. Mori, E. Gauthier, R.S. Finn, M. Toi
Journal: Annals of Oncology (2016)
Mesenchymal Stem Cells Selectively Engraft into Tumor Stroma and Produce Potent Antitumor Proteins In Situ.
Authors: Michael Andreeff, Jennifer Dembinski, Brett M. Hall, Matus Studeny, Xiaoyang Ling, Maria Cabreira-Hansen, A. Kate Sasser, Teresa McQueen, Frederick Lang, Frank C. Marini
Journal: Blood (2006)
head and neck cancer Patient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (nivo) or investigator’s choice (IC): CheckMate 141
Authors: K. Harrington, R.L. Ferris, J. Shaw, F. Taylor, M. Derosa, D. Turner-Bowker, L. Morrissey, K. Cocks, N. Kiyota, M. Gillison, J. Guigay
Journal: Annals of Oncology (2016)
Evaluation of electronic care plan usage and usefulness among breast cancer survivors.
Authors: Mary Sesto, William Gray Hocking, Douglas Wiegmann, Thomas Y Yen, Mindy Gribble, Jamie Zeal, Tamara Koehn, Wenjun Sun, Amye Tevaarwerk
Journal: Journal of Clinical Oncology (2016)

83 Background: Survivorship care plans (SCP) are recommended to improve communication between breast cancer survivors (BCS), primary care, and oncology. Objective evaluation of survivor access of specific care plan content is challenging as commonly-used formats (e.g., paper or electronic file) prevent tracking of usage. This project aimed to evaluate the usage and usefulness of an electronic survivorship care plan (eSCP) that could track access and pages visited. Methods: We recruited 128 BCS from outpatient oncology clinics. 121 BCS received eSCP access via an online secure patient portal; seven received paper copies and are not included in this analysis. The research team customized the portal to track eSCP usage and page visits during the study period (at least 12 weeks of eSCP access). The eSCP consisted of four internal pages (Guide, Treatment Summary, Followup Plan, and Glossary) plus 21 external hyperlinks to survivorship resources. eSCP usefulness and understandability were evaluated using 10-item Likert scales: 1 (not at all useful/very hard to understand to 10 very useful/very easy to understand). Results: 90 out of 121 (74.38%) participants accessed the eSCP. The majority accessed the eSCP within two days of receiving access (N = 70/90, 77.8%) and visited 1 to 3 times (N = 81/90, 90%). Treatment Summary was the most frequently visited internal page (158 visits by 69 participants). Other page usage: Followup Plan (124 visits by 65 participants), Guide (113 visits by 62 participants), and Glossary (46 visits by 31 participants). 34 participants (37.78%) accessed external pages from the eSCP. Participants perceived the overall care plan as useful (8.78, 95% CI [8.38, 9.19]) and easy to understand (8.81, 95% CI [8.47, 9.16]). Conclusions: We found high usage rates among BCS provided an eSCP and the majority perceived the eSCP as useful and easy to understand. Based on favorable assessment and use, it is reasonable for eSCPs to serve as a tool to facilitate communication and care coordination for survivors, especially as access to and use of mobile device technology and electronic patient health portals increase. Minority and rural survivors access and use of such features may require further research.
Primary Intraocular Lymphomas Display A Remarkably Biased Immunoglobulin Heavy Chain Gene Repertoire and Precisely Targeted Somatic Hypermutation Suggesting Antigenic Selection of the Neoplastic Cells
Authors: Nabila Belhouachi, Evangelia Stalika, Bahram Bodaghi, Myriam Boudjoghra, Nathalie Cassoux, Christine Fardeau, Sylvie Baudet, Phuc Le Hoang, Helene Merle-Beral, Kostas Stamatopoulos, Frederic Davi
Journal: Blood (2011)
IgE antibodies to food allergen extracts and to specific food proteins among 616 children in mid-childhood in an unselected birth cohort
Authors: Robert Sullivan, Lisa J. Workman, Alexander J. Schuyler, Sheryl Rifas-Shiman, Emily Oken, Diane R. Gold, Thomas A.E. Platts-Mills
Journal: Journal of Allergy and Clinical Immunology (2017)
Man/machine interface based on the discharge timings of spinal motor neurons after targeted muscle reinnervation
Authors: Dario Farina, Ivan Vujaklija, Massimo Sartori, Tamás Kapelner, Francesco Negro, Ning Jiang, Konstantin Bergmeister, Arash Andalib, Jose Principe, Oskar C. Aszmann
Journal: Nature Biomedical Engineering (2017)
A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-2B
Authors: Christian Recher, Bertrand Coiffier, Corinne Haioun, Christophe Fermé, Thierry Jo Molina, Olivier Casasnovas, Christian Gisselbrecht, Andre Bosly, Guy Laurent, Franck Morschhauser, Herve Ghesquieres, Fabrice Jardin, Serge Bologna, Christophe Fruchart, Danielle Canioni, Bernadette Corront, Jean Gabarre, Christophe Bonnet, Maud Janvier, Herve Tilly
Journal: Blood (2010)
189P Phase II trial of S-1 plus panitumumab for wild-type KRAS unresectable colorectal cancer patients previously treated with 5-fluorouracil (5-FU), oxaliplatin and irinotecan (KSCC1103)
Authors: Y. Sakamoto, Y. Yoshida, H. Ishikawa, T. Ohchi, H. Takeshita, Y. Emi, None Komatsu, T. Sawai, T. Shimose, E. Oki, H. Saeki, Y. Kakeji, Y. Yoshida, H. Baba, Y. Maehara
Journal: Annals of Oncology (2016)
Thalidomide for the treatment of refractory multiple myeloma. decreased plasma concentration of angiogenic growth factors and clinical response
Authors: Tsunayuki Kakimoto, Yutaka Hattori, Shinichiro Okamoto, Tamihiro Kamata, Norihide Satoh, Nobuyuki Takayama, Hiromichi Matsushka, Taketo Yamada, Wenlin Du, Yasuo Ikeda
Journal: Blood (2000)
Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months
Authors: Christian Buske, Eva Hoster, Martin Dreyling, Roswitha Forstpointner, Michael Kneba, Norbert Schmitz, Rudolf Schmits, Bernd Metzner, Marcel Reiser, Eva Lengfelder, Bernhard J Woermann, Harriet Harder, Susanna Hegewisch-Becker, Wolfgang E. Berdel, Georg Hess, Hartmut Eimermacher, Ali Aldaoud, Manfred Planker, Michael Unterhalt, Wolfgang Hiddemann
Journal: Blood (2008)
Modulation of antiangiogenic resistance: Targeting the JAK/STAT3 pathway in glioblastoma.
Authors: John Frederick De Groot, Ji Liang, Ling-Yuan Kong, Jun Wei, Yuji Piao, Greg Fuller, Wei Qiao, Amy B. Heimberger
Journal: Journal of Clinical Oncology (2012)

2011 Background: Determining the mechanism of treatment failure of antiangiogenic therapies would provide insight into either potential combination approaches or salvage therapies. Methods: Tumor and monocyte expression of phosphorylated-signal transducer and activator of transcription 3 (p-STAT3) was compared between recurrent glioblastoma patients treated with either conventional chemotherapy or bevacizumab (BEV), and secondarily validated in murine model systems of intracerebral glioma treated with either BEV or cediranib. The JAK/STAT3 inhibitor AZD1480 alone and in combination with cediranib was evaluated in immunocompetent mice bearing intracerebral GL261 xenografts to evaluate therapeutic synergy. Results: Human glioblastoma patients failing BEV have an increase in intratumoral p-STAT3- expression with a mean number of p-STAT3 expressing cells of 36.5 + 8.6% (n=7) compared to a mean of 20.2 + 4 % (n=5) in patients never receiving antiangiogenic therapy. In a separate cohort of recurrent glioblastoma patients, the up-regulation of p-STAT3 was detected in monocytes within 24 hours after initial BEV administration. In intracranial xenograft models, both BEV and cediranib extended median animal survival time, but during treatment failure BEV increased the mean percentage of p-STAT3-expressing cells to 24.6 + 6.4% (P=0.0011), and cediranib increased this to 16.2 + 1.8% (P=0.0125) relative to 9.0 + 4.4% in controls. Administration of the JAK/STAT3 inhibitor AZD1480 alone and in combination with cediranib reduced tumor hypoxia and infiltration of VEGF inhibitor-induced p-STAT3 macrophages. The combination reduced tumor volume by 80% compared to untreated controls, and by 65% compared to cediranib or AZD1480 treatment alone. Microvascular density and tumor de-differentiation were reduced, indicating that up-regulation of the STAT3 pathway can mediate resistance to antiangiogenic therapy. Conclusions: Cumulatively, these data suggest that a prominent mechanism of failure of anti-VEGF therapy in malignant glioma patients involves up-regulation of the STAT3 pathway, and resistance to antiangiogenic therapy can be modulated with inhibitors of the JAK/STAT pathway.
Characterization of Basophils in Infants in the Microbes, Allergy, Asthma and Pets (MAAP) Birth Cohort
Authors: Erik T. Mann, Suzanne L. Havstad, Alexandra Sitarik, Stacey M. Bellemore, Albert M. Levin, Susan V. Lynch, Dennis R. Ownby, Christine C. Johnson, Nicholas W. Lukacs, Edward M. Zoratti, Kimberley J. Woodcroft, Kevin R. Bobbitt
Journal: Journal of Allergy and Clinical Immunology (2017)
CMV Reactivation after Allogeneic Stem Cell Transplantation Is Associated with a Preponderance of Circulating Late-Stage CMV-Specific CD8+ T Cells.
Authors: Krishna V. Komanduri, Lisa S. St. John, Elizabeth J. Shpall, Richard E. Champlin, Jeffrey J. Molldrem, Evren Ozdemir
Journal: Blood (2005)
Tailoring the approach to multimorbidity in adults with respiratory disease: the NICE guideline
Authors: Lowie E.G.W. Vanfleteren, Martijn A. Spruit, Frits M.E. Franssen
Journal: European Respiratory Journal (2017)

The National Institute for Health and Care Excellence (NICE) previously published guidelines for the management of individual diseases [1]. However, elderly patients commonly suffer from two or more chronic diseases [2]. Multimorbidity is associated with a high treatment and care burden that may impact on the wellbeing of the patient <http://ow.ly/D0xM307Ttoe>
Effect of algenpantucel-L immunotherapy for pancreatic cancer on anti-mesothelin antibody (Ab) titers and correlation with improved overall survival.
Authors: Gabriela R. Rossi, Jeffrey M Hardacre, Mary Frances Mulcahy, Mark S. Talamonti, Jennifer Carrie Obel, Caio Max S. Rocha Lima, Howard Safran, Heinz-Josef Lenz, E. Gabriela Chiorean, Nicholas N. Vahanian, Charles J. Link
Journal: Journal of Clinical Oncology (2013)

3007 Background: Hyperacute rejection of tissues expressing the carbohydrate α(1,3)Gal xenoantigen is a potent innate immune defense mechanism that was leveraged to treat resected pancreatic cancer patients by immunization with genetically modified allogeneic tumor cells expressing αGal moieties (algenpantucel-L). We propose that adding algenpantucel-L to SOC adjuvant therapy may improve survival and induce immunological biomarkers that positively correlate with improved median overall survival (OS). Methods: Open-label, multicenter phase II study evaluating algenpantucel-L+SOC (RTOG-9704: gemcitabine + 5-FU-XRT) for resected pancreatic cancer patients. Endpoints: 1°) disease-free survival (DFS) at 1 year; 2°) OS, toxicity and immunologic analysis. Biomarkers were evaluated including total IgG, complement, CA19-9 levels, anti-αGal Ab, anti-CEA Ab, and anti-membrane-bound recombinant mesothelin (MSLN) Ab. Results: Patients received gemcitabine with 5-FU modulated radiation therapy plus algenpantucel-L. The primary endpoint, 12-month DFS, was 62% and 12-month OS was 86%. All evaluable patients have been in follow-up for ≥ 3 years. We now report OS rates at 3 years of 39% and DFS of 26% at 3 years. Evaluable patients (n=64) were tested for the induction of anti-MSLN Ab where ≥ 25% increase in the anti-MSLN Ab compared to baseline was considered significant (p&lt;0.001). Twenty of 64 patients (31%) had increased anti-MSLN Ab. Patients responding with anti-MSLN Ab had a median OS of 42 months compared to 20 months for patients without sero-conversion. The positive correlation between increased anti-MSLN Ab and improved median OS was statistically significant (p=0.027). Conclusions: The addition of algenpantucel-L to SOC for resected pancreatic cancer may improve survival. In 20/64 patients, algenpantucel-L-induced anti-MSLN Ab responses that correlates with improved survival (median OS 42 vs 20 months). Immunological monitoring of algenpantucel-L immunotherapy with this biomarker is feasible and might predict patient response to therapy. A multi-institutional, phase III study is currently underway (ClinicalTrials.gov NCT01072981). Clinical trial information: NCT00569387.
Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth
Authors: Bojan Bujisic, Aude De Gassart, Rémy Tallant, Olivier Demaria, Léa Zaffalon, Sonia Chelbi, Michel Gilliet, Francesco Bertoni, Fabio Martinon
Journal: Blood (2017)
EXTH-61. NANOPARTICLE DELIVERY TO THE SPINAL CORD VIA DIRECT ADMINISTRATION TO CEREBROSPINAL FLUID
Authors: Kyle T. Householder, Eugene P. Chung, Justine Enns, Rachael Sirianni
Journal: Neuro-Oncology (2016)

Direct delivery of active agents to cerebrospinal fluid (CSF) is one approach used in neuro-oncology for improving drug delivery and activity in the central nervous system; for example, cytarabine-loaded liposomes (DepoCyt©) is a clinically approved formulation for treating lymphomatous meningitis and has also been tested for treatment of leptomeningeal metastasis in medulloblastoma. Although the brain has received substantial attention as a site for tissue-targeted delivery of drug loaded nanocarriers, relatively little is known about the spinal cord. Here, we were interested to engage in deeper characterization of the movement of polymeric nanoparticles through CSF to deliver encapsulated molecules to the brain and spinal cord. First, we utilized polystyrene nanoparticles to study size-dependent distribution and clearance of nanoparticles in the spinal cord after fourth ventricle injection in healthy mice. Next, we encapsulated DiR, a lipophilic drug surrogate, within 130nm poly(lactide)-b-poly(ethylene glycol) polymeric nanoparticles to evaluate the differential fate of nanoparticle versus payload. Our preliminary data show that nanoparticles administered to the fourth ventricle rapidly distribute down the central canal of the spinal cord at 30 min and at 2 hours post-injection, although the distribution of DiR appears to be more concentrated near the injection site, even 6 hours after injection. We observed penetration of nanoparticles hundreds of microns into the spinal cord parenchyma, which may be facilitated by nanoparticle movement through perivascular spaces. Finally, we have encapsulated a small library of chemotherapeutic agents within nanoparticles and are currently evaluating nanoparticle-drug tolerability and activity when administered directly to the CSF. These studies deepen our understanding of CSF as a drug delivery medium and bring us closer to our long-term goal of developing targeted nanoparticle therapeutics for treating metastatic disease in the spinal cord.
Stanisław Ostrowski, MD—The One State President Among Dermatologists in the World
Authors: Martyna Woltanowska, Andrzej Wincewicz
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
A Study of Predictors of Clinical Outcomes and Healthcare Utilization in Children with Sickle Cell Disease Undergoing Allogeneic Hematopoietic Cell Transplantation
Authors: Prakash Satwani, Ruta Brazauskas, Staci D. Arnold, Naya He, Yimei Li, Richard Aplenc, Matt Hall, Yoshiko Atsuta, Jignesh D Dalal, Theresa Hahn, ZheZhen Jin, Carmem Sales-Bonfim, Nandita Khera, Wael Saber
Journal: Blood (2015)